热门资讯> 正文
Enveric Biosciences GAAP每股收益为-10.81美元
2025-11-15 05:49
- Enveric Biosciences press release (ENVB): Q3 GAAP EPS of -$10.81.
- The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges.
- As of September 30, 2025, Enveric had cash and cash equivalents of $3.8 million. The Company continues to fund its operations through the use of various financing tools.
- The Company has raised net proceeds of $7.9 million for the nine months ended September 30, 2025.
More on Enveric Biosciences
- AbbVie could face patent battle over depression asset gained in Gilgamesh deal
- Seeking Alpha’s Quant Rating on Enveric Biosciences
- Financial information for Enveric Biosciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
